| Name | PLX5622 |
| Description | PLX5622 is an orally active small-molecule CSF1R inhibitor that selectively depletes microglia in the brains of mice and rats. It is commonly used to establish models related to microglia-associated neuroinflammation, neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease), brain injury, and neuroimmune regulation. This product is also available as a premixed diet version (C2005 PLX5622 in AIN-76A Diet (1200 ppm)), eliminating the need for self-preparation and offering superior stability and reproducibility. |
| In vitro | METHODS: CX CR1+/GFP mouse-derived mixed glial cell cultures were treated with PLX5622 (0.1-10 µM) for 7 days and cell counts were assayed by Flow cytometry.
RESULTS: Although there was a dose-dependent decrease in microglia numbers under PLX5622, no decrease in GFAP+ astrocytes was seen, but rather a gradual increase, along with a decrease in PDGFR-a OPC. [1]
METHODS: Cerebellar sections prepared from PLP-eGFP mouse pups were treated with PLX5622 (1-20 µM) for 3 days followed by Immunostaining.
RESULTS: After three days of treatment, PLX5622 at concentrations greater than 2 µM eliminated more than 95% of microglia. [2] |
| In vivo | METHODS: To study in vivo activity, PLX5622 (1200 mg/kg) was administered to PLP eGFP mice by feed for 7-21 days.
RESULTS: PLX5622 was effective in depleting microglia in the central nervous system of adult mice. treatment with PLX5622 for 7 days had no effect on oligodendrocyte progenitor cell populations; however, a mild reduction was observed after 21 days in some central nervous system regions. [2] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 65 mg/mL (164.39 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 7.9 mg/mL (19.98 mM), Suspension.
|
| Keywords | preceding | PLX5622 | PLX 5622 | penetrant | pathology | orally | microglial | Inhibitor | inhibit | elimination | CSF-1R | CSF1R | CSF-1 receptor | colony stimulating factor 1 receptor | c-Fms | cFms | brain |
| Inhibitors Related | c-Fms-IN-3 | PLX647 | Sotuletinib | Tandutinib | AZD7507 | GW2580 | Pexidartinib | c-Fms-IN-13 | GW786034B | Onatasertib | Dovitinib | Cerdulatinib hydrochloride |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Drug Repurposing Compound Library | CNS-Penetrant Compound Library | Inhibitor Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
